Treatment of Unstable 31.A2 and 31.A3 Trochanteric Fractures. Randomised Comparison of the Proximal Femoral Nail PFN-A Short and the PFN-A Long.
NCT ID: NCT02038686
Last Updated: 2017-02-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
188 participants
INTERVENTIONAL
2014-01-31
2017-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Controversy exists with regard to whether to treat AO/OTA (Orthopaedic Trauma Association) 32.A2 - 32-A3 fractures of the proximal part of the femur with an intramedullary short PFN-A or long PFN-A. A prospective, randomized, controlled trial is performed to compare the outcome treatment of these unstable fractures of the proximal part of the femur with either a short PFN-A (170-240mm) or long PFN-A (300-420mm).
2. Objectives and Hypothesis The hypothesis is that the Short PFN-A would have fewer complications than Long PFN-A
Main Objective: Is defined as Total number of complications between PFN-A short and PFN-A long. Outcome measures were subdivided into preoperative, perioperative and post-operative. Follow up data at four weeks, three months and one year.
Secondary objectives: Complete and uneventful radiological and clinical healing of the fracture. Revision operations (related to the failure of primary treatment) and mortality. Baseline characteristics were documented pre-operatively: Outcome measures were subdivided into intra-operative, post-operative and follow up data at four weeks, three months and one year.
3. Methodology: One hundred and eighty eight patients presenting with an AO/OTA 31-A2 and 31-A3 fracture of the proximal part of the femur will be randomized, at the time of the admission, to fixation with use either a short PFN-A or a long PFN-A.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment of Unstable Trochanteric Fractures With the Proximal Femoral Nail - Antirotation (PFNA)-Asia
NCT00873548
Periprosthetic Distal Femur Fracture
NCT01973712
Intramedullary Devices for the Treatment of Unstable Pertrochanteric Fractures
NCT02074969
Proximal Femoral Nail Antirotation (PFNA) Versus PFNA Augmentation
NCT01473082
Influence of Static Distal Locking of a Short Proximal Femoral Nail
NCT06357312
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard PFN-A
Patients with unstable proximal femoral fractures treated with PFN-A short nail (170-240mm)
PFN-A
Long PFN-A
Patients with unstable proximal femoral fractures treated with PFN-A long nail (300-420mm)
PFN-A
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PFN-A
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with trochanteric fracture 31.A2 and 31.A3 AO classification for long bones
* Patients that accept to participate on the study under consent
Exclusion Criteria
* Combination of fractures in the proximal femur.
* Pathological fractures.
* Diaphyseal femoral fractures.
* Rejection of surgery by the patient.
* Contraindications to the use of either implants studied.
* Patients who do not wish to participate in this study
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Parc Taulí Hospital Universitari
OTHER
Ferran Fillat Gomà
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ferran Fillat Gomà
Medical Doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ferran Fillat-Gomà, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Universitario Parc Tauli de Sabadell
Joan Murias-Álvarez, MD
Role: STUDY_DIRECTOR
Hospital Universitario Parc Tauli de Sabadell
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Universitario Parc Taulí de Sabadell
Sabadell, Barcelona, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CSPTCOT2013/01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.